Ignite Creation Date:
2024-10-25 @ 8:01 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06539208
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-01
Brief Title:
A Phase IIIaOpen-label Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy ATTR-PN or Transthyretin Amyloidosis Cardiomyopathy ATTR-CM
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase IIIaOpen-label Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy ATTR-PN or Transthyretin Amyloidosis Cardiomyopathy ATTR-CM
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will be conducted to evaluate the safety tolerability pharmacokinetics PK and pharmacodynamics PD of YOLT-201 in participants with hereditary transthyretin amyloidosis with polyneuropathy ATTRv-PN and participants with hereditary transthyretin amyloidosis with cardiomyopathy ATTRv-CM
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None